Treatment with specific prebiotics or probiotics prevents the development of lung emphysema in a mouse model of COPD

K.A.T. Verheijden, J. Van Bergenhenegouwen, J. Garssen, G.F.G. Bezemer, A.D. Kraneveld, G. Folkerts

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Treatmentwith dietary fibers (prebiotics) and/or lactic acid producing bacteria (probiotics) has beneficial effects in various models of allergic asthma. Beneficial effects of pre- and probiotics have beenfound regarding the suppression of airway hyperresponsiveness and airway inflammation. Chronic obstructive pulmonary disease (COPD) is a major health problem and associatedwith pulmonary inflammation and emphysema. Therefore, we have examined the effects of prebiotic fiber mixture of short-chain galacto-oligosaccharides and long- chain fructo-oligosaccharides (GOS/ FOS) and two probiotics strains, Lactobacillus rhamnosis and Bifidobacterium breve in amurinemodel for COPD. BALB/c micewere subjected to biweekly intra nasal (i.n.) instillation with lipopolysaccharide (LPS, 5 μg/ mouse) to induce lung emphysema. Treatment comprised of daily (5× per week) intra-gastric supplementation with either a 9:1 mixture of shortchain galacto-oligosaccharides and long-chain fructo-oligosaccharides (GOS/FOS), B. breve (BF06) or L. rhamnosus (BF02) (Fig. 1). LPS treatment significantly induced an influx of leukocytes in the bronchoalveolar lavage (BAL) fluid. Treatment with either BF02 or BF06 was able to reduce the influx of macrophages into BAL fluid (data not shown). Neutrophil influx in BAL fluid could be attenuated by GOS/FOS treatment (Fig. 2). Furthermore, treatment with GOS/FOS, BF02 or BF06 was able to reduce LPS induced alveolar damage (assessed by increases in mean linear intercept) (Fig. 3) and right ventricle heart hypertrophy (Fig. 4). These findings suggest that, next to specific probiotics, a specific mixture of prebiotics might be beneficial as nutritional intervention in patients suffering from COPD. Part of this study was performed within the framework of Dutch TI-Pharma (project number Di1-101). (Figure presented) .
Original languageEnglish
Pages (from-to)12-13
Number of pages2
JournalEuropean Journal of Pharmacology
Volume668
DOIs
Publication statusPublished - 1 Sept 2011

Keywords

  • Probiotics
  • Prebiotics
  • Lipopolysaccharide
  • Oligosaccharides
  • probiotic agent
  • prebiotic agent
  • lipopolysaccharide
  • oligosaccharide
  • fructose oligosaccharide
  • galactose oligosaccharide
  • lactic acid
  • nonoxinol 9
  • nutrition
  • mouse
  • lung emphysema
  • model
  • liquid
  • airway
  • heart hypertrophy
  • patient
  • human
  • dietary fiber
  • bacterium
  • allergic asthma
  • inflammation
  • pneumonia
  • chronic obstructive lung disease
  • emphysema
  • fiber
  • Lactobacillus
  • Bifidobacterium breve
  • supplementation
  • leukocyte
  • lung lavage
  • macrophage
  • neutrophil
  • heart right ventricle
  • health

Fingerprint

Dive into the research topics of 'Treatment with specific prebiotics or probiotics prevents the development of lung emphysema in a mouse model of COPD'. Together they form a unique fingerprint.

Cite this